Just an average investor... primarily in American equity and bonds. (Important Note: My articles, blogs, comments, reference links and messages are not intended to be investment advisements; or to value securities. Examples and considerations are hypothetical and educational. Please consult a financial advisor before making investments in any security. Thank you for reading!)
Nelson Alves is a professional investor, established in Portugal. He started his career in 2007 right at the start of the biggest financial crisis since 1929. Until 2011 he worked in several trading desks. His main influences are Philip Fisher and Warren Buffet. Nelson is looking to help small investors on the task of preserving and increasing their savings’ funds.
Being a thoroughly student of several investment approaches, he believes that the equity markets should be on service of both small and institutional investors, and therefore every citizen should be able to reclaim his fair share of the long-term growing prosperity around the world.
Software Engineer - late 50s
Like to hold a combination of index funds (when appropriate), short-term bonds, some managed funds, and a focused selection of individual stocks (preferably with no more debt that 4 times annual earnings)
Prefer simple to understand stocks, no biotech and minimal tech individual stock holdings.
I'm the author of five published books, an investor and a cancer survivor. I got my start thirty-two years ago doing research for a UCLA economics professor who wrote a stock-picking newsletter. I have been involved in information technology, dental and medical research (former clinical editor with Dentistry Today magazine) and software design. Right now, I'm finishing my sixth book, and writing articles on Seeking Alpha for others who (like me) enjoy doing extensive investment research and profiting from it.
Over 20 years experience as an equity analyst/portfolio manager, convertible portfolio manager, high yield/leverage loan credit analyst, and banking/credit analyst at several financial institutions. Strong expertise in following healthcare companies in all sub-sectors and market capitalization. Also, have covered telecommunications, technology, consumer cyclical and consumer staples companies as well.
MTR Investors Group goal is to provide the best Covered / Naked, Credit Spread, and Iron Condor Option Screeer on the web. Screen over 3,100 stocks and over 270,000 options in seconds to find the best possible trades!
Option writers use our screener to find options trades that have the highest probability of expiring worthless.
Attempting to find profitable option trades on over 3,100 stocks and over 250,000 options, and millions of Credit Spread and Iron Condor combinations is a huge effort. The MTR option screener simplifies that process and will discover trades that otherwise would be missed.
This is an end of day screening service. It is geared toward traders that look for trading opportunities after hours to prepare for the next trading day.
We use Stock Market Scout (SMS) as a model to indicate allocating cash to an index ETF (such as SPY) by going long on Green, cash on Yellow, short on Red (or stay in cash). This is not a recommendation to buy or sell SPY.
We are proud to offer powerful tools for free or at price point that allows any investor to have an edge.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.